Previous 10 | Next 10 |
2024-04-01 12:43:41 ET More on Zymeworks Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 ...
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appoin...
2024-03-27 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-16 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-08 10:18:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the li...
2024-03-07 17:04:26 ET More on Zymeworks Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 ...
2024-03-06 23:17:10 ET Zymeworks Inc. (ZYME) Q4 2023 Earnings Conference Call March 6, 2024, 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and CFO Paul Moore - Chief Scientific Officer K...
2024-03-06 17:42:05 ET More on Zymeworks Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks Non-GAAP EPS of -$0.16 beats by $0.28, revenue of $16.92M misses by $0.74M Read the full article on Seeking Alpha For further details see: ...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-06 16:20:17 ET More on Zymeworks Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tai...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...